FMO5 and stroke disorder: Another, less specific inhibitor that also targets molecules other than NADPH oxidases [36],[37], apocynin, had no effect on infarct size or functional outcome when given post-stroke and did not reduce the formation of ROS in vivo (Figure 4B and 4C).